高容量注射治疗慢性跟腱中段病的随机对照试验
这项在荷兰某大型区综合医院运动医学科开展的患者与评估者双盲、安慰剂对照随机临床试验,纳入80例经临床诊断且超声显示有新生血管形成的慢性跟腱中段病成人(18-70岁),比较在24周运动计划(常规照护)基础上加用一次50 mL高容量注射(生理盐水+利多卡因)与一次2 mL安慰剂注射的效果。主要结局为24周时VISA-A问卷评估的疼痛与功能,结果显示两组VISA-A评分随时间变化无差异(24周调整组间差异0.5分,95%CI -17.8至18.8),患者满意度与恢复运动等次要结局亦无显著组间差异。结论为在常规照护基础上加用无皮质激素的高容量注射对慢性跟腱中段病患者症状减轻无效,基于此发现不建议该患者群体使用高容量注射。
要点
- 高容量注射加常规照护与安慰剂加常规照护相比,24周VISA-A评分无差异。
- 24周患者满意度两组分别为57%与49%,差异无统计学意义(P=0.50)。
- 恢复期望运动两组分别为52%与61%,差异无统计学意义(P=0.65)。
核心结论
- 在常规照护基础上加用无皮质激素的高容量注射对慢性跟腱中段病患者症状减轻无效。
- 基于该研究结果,不建议在该患者群体中使用高容量注射。
研究设计与样本
- 患者与评估者双盲、安慰剂对照随机临床试验,在荷兰某大型区综合医院运动医学科开展。
- 纳入80例临床诊断慢性跟腱中段病且超声显示新生血管形成的成人(18-70岁)。
- 39例随机至高容量注射组,41例随机至安慰剂组,两组均执行24周运动计划(常规照护)。
- 干预组于基线接受一次50 mL生理盐水与利多卡因高容量注射,安慰剂组接受一次2 mL生理盐水与利多卡因注射。
- 主要结局为24周时VISA-A问卷评估的疼痛与功能,采用广义估计方程模型分析。
主要发现
- 高容量注射组估计平均VISA-A评分从基线40.4(95%CI 32.0至48.7)改善至24周59.1(50.4至67.8)。
- 安慰剂组估计平均VISA-A评分从基线36.9(27.1至46.8)改善至24周58.5(47.9至69.1)。
- VISA-A评分随时间变化两组无差异,24周调整组间差异0.5分(95%CI -17.8至18.8)。
- 24周患者满意度两组分别为21/37(57%)与19/39(49%),P=0.50。
- 24周恢复期望运动在运动人群中的比例两组分别为15/29(52%)与19/31(61%),P=0.65。
关键数值与推荐
- 主要结局为24周VISA-A问卷评分,组间差异以调整后均值差及95%CI表示。
- 患者满意度与恢复运动以例数/可评估例数(百分比)及P值报告。
- 其他次要结局包括超声多普勒血流程度、10次跳测试视觉模拟评分、腓肠肌与比目鱼肌力量及柔韧性、神经病理性疼痛pain detect问卷及疼痛应对量表,两组均无差异。
- 仅1例(1%)失访。
临床怎么用
- 对于慢性跟腱中段病成人,在常规运动计划基础上加用无皮质激素的高容量注射不应作为改善症状的推荐治疗。
- 临床决策应基于常规照护,高容量注射缺乏优于安慰剂的证据。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether a high volume injection without corticosteroids improves clinical outcome in addition to usual care for adults with chronic midportion Achilles tendinopathy. DESIGN: Patient and assessor blinded, placebo controlled randomised clinical trial. SETTING: Sports medicine department of a large district general hospital, the Netherlands. PARTICIPANTS: 80 adults (aged 18-70 years) with clinically diagnosed chronic midportion Achilles tendinopathy and neovascularisation on ultrasonography. 39 were randomised to a high volume injection without corticosteroids and 41 to placebo. INTERVENTIONS: Participants were instructed to perform an exercise programme for 24 weeks (usual care) combined with one 50 mL high volume injection of saline and lidocaine (intervention group) or one 2 mL placebo injection of saline and lidocaine (placebo group) at baseline. MAIN OUTCOME MEASURES: Primary outcome was pain and function assessed using the validated Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire at 24 weeks (analysed using a generalised estimation equations model). Secondary outcomes were patient satisfaction, return to sport, degree of ultrasonographic Doppler flow, visual analogue scale on 10 hop test, power and flexibility of the gastrocnemius and soleus muscles, pain detect questionnaire for neuropathic pain, and pain coping inventory. Participants were evaluated at baseline and at 2, 6, 12, and 24 weeks. RESULTS: Only one participant (1%) was lost to follow-up. The estimated mean VISA-A score improved significantly, from 40.4 (95% confidence interval 32.0 to 48.7) at baseline to 59.1 (50.4 to 67.8) at 24 weeks in the high volume injection group and from 36.9 (27.1 to 46.8) to 58.5 (47.9 to 69.1) in the placebo group. The VISA-A score over time did not differ between the groups (adjusted between group difference at 24 weeks 0.5 points, 95% confidence interval -17.8 to 18.8). No significant between group differences were found for patient satisfaction (21/37 (57%) v 19/39 (49%) patients, P=0.50) and return to desired sport (15/29 (52%) v 19/31 (61%) patients active in sports, P=0.65) at 24 weeks. None of the other secondary outcomes differed between the two groups. CONCLUSIONS: A high volume injection without corticosteroids in addition to usual care is not effective for symptom reduction in patients with chronic midportion Achilles tendinopathy. On the basis of our findings, we cannot recommend the use of a high volume injection in this patient group. TRIAL REGISTRATION: ClinicalTrials.gov NCT02996409.
引用
- van der Vlist AC, van Oosterom RF, van Veldhoven PLJ, et al. Effectiveness of a high volume injection as treatment for chronic Achilles tendinopathy: randomised controlled trial. BMJ. 2020. PMID: 33315586. doi:10.1136/bmj.m3027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。